The maternal-fetal transfer of lamivudine in the ex vivo human placenta. 1997

S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235-9032, USA.

OBJECTIVE Our purpose was to measure the transfer of lamivudine ([-]-2'-deoxy-3'-thiacytidine) across the human placenta both alone and in the presence of zidovudine. METHODS Nine placentas from term, elective cesarean deliveries were analyzed with use of the ex vivo single cotyledon perfusion system. Antipyrine was used as the reference compound to measure the clearance index values of lamivudine alone and in combination with zidovudine. Lamivudine concentrations in the perfusates and tissues were quantified by high-pressure liquid chromatography. RESULTS The clearance index of lamivudine at a maternal concentration of 1.39 micrograms/ml was 0.23 +/- 0.14. At a peak concentration of 14.68 micrograms/ml the clearance index was 0.14 +/- 0.06. These index values did not significantly change in the presence of 1 or 10 micrograms/ml of zidovudine. In a closed recirculating system the fetal lamivudine concentration increased as more lamivudine was added to the maternal perfusate. The addition of zidovudine did not influence this transfer. CONCLUSIONS Lamivudine appears to cross the placenta by simple diffusion and its transfer does not appear to be altered by zidovudine.

UI MeSH Term Description Entries
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
January 1995, American journal of obstetrics and gynecology,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
November 2014, Reproductive toxicology (Elmsford, N.Y.),
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
December 2005, Infectious diseases in obstetrics and gynecology,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
April 2001, Placenta,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
April 2008, American journal of obstetrics and gynecology,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
July 2001, American journal of obstetrics and gynecology,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
July 2016, Reproductive toxicology (Elmsford, N.Y.),
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
January 1990, Developmental pharmacology and therapeutics,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
September 2021, Placenta,
S L Bloom, and K M Dias, and R E Bawdon, and L C Gilstrap
January 2024, Current research in toxicology,
Copied contents to your clipboard!